Immunoglobulins to mitigate paraneoplastic Lambert Eaton Myasthenic Syndrome under checkpoint inhibition in Merkel cell carcinoma

Immunoglobulins to mitigate paraneoplastic Lambert Eaton Myasthenic Syndrome under checkpoint inhibition in Merkel cell carcinoma

Lambert-Eaton myasthenic syndrome (LEMS) is a rare, autoimmune or paraneoplastic condition characterized by muscle weakness and fatigability. In cancer therapy, immune checkpoint inhibitors (ICI) sensitize the immune system for tumor antigens. We report a 62-year-old, female patient with paraneoplas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurological research and practice 2020-12, Vol.2 (1), p.52-3, Article 52
Hauptverfasser: Dohrn, Maike F, Schöne, Ulrike, Küppers, Charlotte, Christen, Deborah, Schulz, Jörg B, Gess, Burkhard, Tauber, Simone
Format: Artikel
Sprache:eng
Schlagworte:
Antigen (tumor-associated)
Immune checkpoint inhibitors
Immune system
Immunoglobulins
Intravenous administration
Lambert-Eaton myasthenic syndrome
Letter to the Editor
Monoclonal antibodies
Neuromuscular junctions
Remission
Skin cancer
Targeted cancer therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Lambert-Eaton myasthenic syndrome (LEMS) is a rare, autoimmune or paraneoplastic condition characterized by muscle weakness and fatigability. In cancer therapy, immune checkpoint inhibitors (ICI) sensitize the immune system for tumor antigens. We report a 62-year-old, female patient with paraneoplastic LEMS as first manifestation of Merkel cell carcinoma. Under avelumab, the LEMS exacerbated with worsening of limb weakness and a severely reduced vital capacity (
ISSN:2524-3489
2524-3489
DOI:10.1186/s42466-020-00099-5